The FDA has approved concizumab-mtci, a daily subcutaneous treatment to reduce bleeding for patients with hemophilia who have clotting factor inhibitors.
A recent phase 3 trial demonstrated that a personalized approach using ibrutinib-venetoclax therapy, based on measurable residual disease, improves progression-free survival and overall survival in patients...
A specialized inpatient sickle cell disease (SCD) consult service led to improved pain management, shorter hospital stays and expanded use of individualized pain plans for patients with SCD.
Researchers report on the first safety and efficacy of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody, for patients with relapsed/refractory Mantle cell lymphoma. This study was presented at...
The OASIS trial evaluates the efficacy of ibrutinib, venetoclax, and obinutuzumab in newly diagnosed mantle cell lymphoma, reporting a 5-year progression-free survival (PFS) rate of 80% and overall survival...
Researchers analyzed data from a nationwide cohort to evaluate the effectiveness of covalent Bruton tyrosine kinase inhibitors, used either as monotherapy or in combination with anti-CD20 monoclonal...
A retrospective study highlights the safety and feasibility of outpatient administration of brexucabtagene autoleucel for patients with acute lymphoblastic leukemia and mantle cell lymphoma, showing...
The FDA has approved a novel therapy for patients with hemophilia A or B without inhibitors. Clinical trials showed it significantly reduces bleeding episodes by targeting a new protein in the blood...
The FDA has approved a novel therapy for patients with hemophilia A or B without inhibitors. Clinical trials showed it significantly reduces bleeding episodes by targeting a new protein in the blood...
In a long-term follow-up to SIERRA, a multicenter, randomized, controlled phase 3 study, researchers found that patients 55 years of age or older with active relapsed or refractory acute myeloid leukemia...
